Dana dhuwit diétung saben saham CorMedix Therapeutics (CRMD)

CorMedix Inc. - logo grafis emiten CRMD

CorMedix Inc. (CRMD) revenues are based on the implementation of antimicrobial agents in dialysis, while the financial reserve remains stable. Global political instability and sanctions are currently hindering the certification of new drugs. The team consists of academic scientists motivated by stock options. The trend of the cash cushion per share illustrates the business's liquidity, and 4.48 shows the level of this metric.

Dana dhuwit saben saham: CorMedix Inc. (CRMD) kanggo 04.07.2022 - 20.11.2026

Rincian analitis perusahaan CorMedix Inc.

- rega saiki lan proyeksi nilai saham:
- indikator anane dhuwit lan arus kas:
Ringkesan analisis perusahaan:CRMD (CorMedix Corp)
Barang unggulan CorMedix

CorMedix Inc. (CRMD) dominance in the catheter infection prevention segment and its strong pricing power create a solid foundation for capitalization. An analysis of the current liquidity per share, calculated as the ratio of cash to the number of issued securities, allows for an assessment of the business's financial autonomy and its ability to fund expansion without external borrowing, confirming long-term capital stability.